O M Dean
Overview
Explore the profile of O M Dean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
654
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jayaram L, King P, Hunt J, Lim M, Park C, Hu E, et al.
Pulm Pharmacol Ther
. 2023 Dec;
84:102283.
PMID: 38141851
Background: High dose N acetylcysteine (NAC), a mucolytic, anti-inflammatory and antioxidant agent has been shown to significantly reduce exacerbations, and improve quality of life in placebo controlled, double blind randomised...
2.
BARNES R, Skvarc D, Fitzgerald P, Berk M, Dean O, Dodd S, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2023 Jul;
127:110820.
PMID: 37406796
Objectives: Repetitive transcranial magnetic stimulation (rTMS) is a level 1a evidence-based treatment for major depression, but high cost of care and limited effectiveness in naturalistic cohorts have been lingering criticisms....
3.
Bortolasci C, Voigt C, Turner A, Mohebbi M, Gray L, Dodd S, et al.
Acta Neuropsychiatr
. 2020 Jul;
32(6):313-320.
PMID: 32600481
Objective: The aims of this study were to evaluate changes in inflammatory and oxidative stress levels following treatment with N-acetylcysteine (NAC) or mitochondrial-enhancing agents (CT), and to assess the how...
4.
Cotton S, Berk M, Watson A, Wood S, Allott K, Bartholomeusz C, et al.
Trials
. 2019 Nov;
20(1):658.
PMID: 31779696
Background: First-episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, evidence suggests that the illness course can be improved if appropriate treatments are given...
5.
Mohebbi M, Dodd S, Dean O, Berk M
Eur Psychiatry
. 2018 Jun;
53:17-22.
PMID: 29859377
Background: Concordant with an increased emphasis on consumer engagement, the Patient Global Impression Scale of Improvement (PGI-I) is commonly used as an outcome measure in studies evaluating the efficacy of...
6.
Rapado-Castro M, Dodd S, Bush A, Malhi G, Skvarc D, On Z, et al.
Psychol Med
. 2016 Nov;
47(5):866-876.
PMID: 27894373
Background: Cognitive deficits are predictors of functional outcome in patients with psychosis. While conventional antipsychotics are relatively effective on positive symptoms, their impact on negative and cognitive symptoms is limited....
7.
Fernandes B, Steiner J, Bernstein H, Dodd S, Pasco J, Dean O, et al.
Mol Psychiatry
. 2015 Jul;
21(4):554-64.
PMID: 26169974
The inflammatory hypothesis of schizophrenia (SZ) posits that inflammatory processes and neural-immune interactions are involved in its pathogenesis, and may underpin some of its neurobiological correlates. SZ is the psychiatric...
8.
Dean O, Jeavons S, Malhi G, Cotton S, Tanious M, Kohlmann K, et al.
Afr J Psychiatry (Johannesbg)
. 2013 Sep;
16(4):238, 240.
PMID: 24051561
No abstract available.
9.
Magalhaes P, Dean O, Bush A, Copolov D, Weisinger D, Malhi G, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2012 Jan;
37(1):132-5.
PMID: 22212173
Objectives: Bipolar disorder (BD) is intricately associated with chronic clinical conditions. Medical comorbidity is not only more prevalent in mood disorders, but is associated with increased costs, cognitive impairment and,...
10.
Berk M, Kapczinski F, Andreazza A, Dean O, Giorlando F, Maes M, et al.
Neurosci Biobehav Rev
. 2010 Oct;
35(3):804-17.
PMID: 20934453
There is now strong evidence of progressive neuropathological processes in bipolar disorder (BD). On this basis, the current understanding of the neurobiology of BD has shifted from an initial focus...